“ Adherence over the first 12 months of therapy ranged from 82% to 88% in the three data sets. Between 19% and 28% of women had fewer than 80% of days covered. For women with 36 months of continuous eligibility, the mean adherence decreased each year, ranging from 78% to 86% in year 1 to 62% to 79% in year 3 within the three data sets.
— Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer — Partridge et al. 26 (4): 556 — Journal of Clinical Oncology Adherence rates based on longitudinal claims data from three large commercialhealth programs for more than 12,000 women with early stage breast cancer
